Abstract
Introduction

37
Chronic myeloid leukemia (CML) is a myeloid stem cell disease characterized by the BCR- 
Results
82
TNT formation in Kcl-22 cells is significantly increased following treatment with IFNα or
83
TKIs
84
In order to investigate the presence of TNTs between CML cells, primary bone marrow CML 85 cells were cultured for 24 h on fibronectin coated surfaces and TNTs were quantified as earlier 
103
were not observed for the K562 cells (Fig 1B) TNT formation in Kcl-22 cells only (Fig 1D) . Cell viability after TKI treatment was verified by
110
Hoechst staining, the K562 was the most sensitive cell line towards nilotinib treatment for 24 h 111 (16.9 % for K562 and 10.2 % for Kcl-22) and we therefore investigated 1 hour treatment with 112 nilotinib (100 nM) however, TNT induction was only observed in the Kcl-22 cells (Fig 1E) .
113
Scanning electron microscopy revealed that the TNTs were thin cell-to-cell connecting structures 114 which could contain bulges, indicating potential intercellular transport (Fig 1F, arrow) .
115
Immunofluorescence microscopy of nilotinib-treated Kcl-22 cells (1 h) revealed the presence of 116 F-actin and the absence of β-tubulin in the TNTs (Fig 1G) . The nilotinib-treated Kcl-22 cells also 117 went through a change in morphology from spherical semi-attached cells to more spread-out and 118 firmly attached cells (Fig 1G) . The critical role of F-actin in these TNTs was further examined by before treatment with CytD (2µM) for 20 min followed by a second TNT quantification (Fig 1H) .
122
This demonstrated that the CytD treatment resulted in TNT collapse and less prominent cell 123 stretching (Fig 1H, I ). These data demonstrate that inhibition of BCR-ABL1 by nilotinib induces 124 the formation of TNTs in a manner dependent upon actin polymerization. (Fig 2A) and also IL-3-131 independent growth (Supplementary Fig S2A) . BCR-ABL1 induction resulted in more spherical 132 morphology and less firmly fibronectin-attached cells on the coated plastic culture well (Fig 2B) .
133
Interestingly, expression of BCR-ABL1 was also accompanied by down-regulation of TNTs (Fig   134   2C ). Conversely, treatment of Kcl-22 cells with nilotinib (100 nM) for 1 h resulted in less 135 spherical cell morphology, increased adherence and TNT formation ( Fig 1E, I and 2D). We without significant changes in cell surface area (Fig 3A-B) . Strikingly, these nilotinib and IFNα-151 induced changes in cell morphology were completely blocked by pre-incubation with the β1 152 integrin blocking antibody (Fig 3C-D) . When measuring cell motility by time-lapse microscopy,
153
we found that the IFNα and nilotinib-induced change in cell morphology was associated with a 154 significant decrease in cell motility. Conversely, pre-treatment with the β1 blocking antibody 155 resulted in increased cell motility ( Figure 3C-D expression and activity of Rho and higher activity of Cdc42 (Fig 4 B and C) . However,
168
treatments with nilotinib did not result in any major changes in total protein expression or in the 169 activity of these GTPases (Fig 4A-C Interestingly, both increased adhesion and change in morphology was observed in the two CML 259 cell lines after imatinib treatment, accompanied by a significant increase in TNT formation. The RhoGTPases are known to have an impact on F-actin and cell mobility, and also to be SAOS-2 (Fig 5A) or when incubated in conditioned medium from MSCs (Fig 5B) . This with CXCL8 or VEGF together with nilotinib treatment, CXCL8, but not VEGF, inhibited the 296 nilotinib-induced TNT formation (Fig 5C, D) .
297
Multiple studies have demonstrated the pro-survival properties of CXCL8 on CML cells, and also determined by May-Grünwald staining (Fig 6C and D) , but the total surface CXCR2 expression 320 remained unchanged (Fig 6E) .
321
Taken together, we find that imatinib treatment induces TNT formation in the CML cell lines increased cell adhesion involving β1-integrin, potentially also including the BCR-ABL1/CXCL8 325 pathway (Fig 7) . The functional consequences of TNT induction needs to be further investigated. 
Mem-GFP transduced cells
341
The memGFP-Kcl-22 and mem-GFP-K562 cells were generated by transducing the cells with 
Antibodies and reagents
368
The following primary antibodies were used for immunofluorescence and/or immunoblotting: 
419
Tracking of cells was performed using metamorph and the chemotaxis and migration (Ibidi
420
GmbH) plugin to ImageJ was performed to calculate accumulated distance and to make trajectory 
Scanning electron microscopy (SEM)
438 500 0000 cells were seeded on L-lysine pre-coated coverslips followed by incubation at 37°C 439 overnight before fixed (4 % glutaraldehyde in 0.2 M Na-cacodylate in buffer diluted 1:1 with 440 medium) for 2 h at RT. Cells were carefully washed three times for 15 min using 0.1 M Na- from BioRad, transferred to PVDF membranes using Pierce G2 fast blotter (Thermo Scientific).
453
Membranes were blocked for 1h at RT in 5% fat-free drymilk or 3% BSA in TBST, incubated
454
with primary antibody at 4°C overnight. Membranes were washed with TBST followed by GDP as a negative control. In each reaction 500 µg cell lysates were used added 10 mM EDTA 472 and 0.1 mM GTPγS or GDP followed by incubation at 30°C for 15 min with shaking (300RPM).
473
The reaction was stopped by adding 60 mM MgCl 2 on ice. The pull-down was performed with ±standard deviation (SD) and unpaired t-test was performed to investigate significance 842 (P**<0.005, P***<0.001, n.s= not significant). 
855
Results from unpaired t-tests (P*<0.05, P**<0.005). 
